Trial · NCT07894900
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Local Relapse Free Survival | From the date of radiotherapy end until the date of local progression or date of death from any cause, whichever came first, assessed up to 5 years | Local control of the disease (at the treated site) |
| Primary | Biochemical Relapse Free Survival | From the date of radiotherapy end until the date of biochemical progression or date of death from any cause, whichever came first, assessed up to 5 years | Biochemical control for prostate cancer |
| Primary | Obliteration rate | Up to 5 years after the treatment | Obliteration rate of arteriovenous malformations |
| Primary | Improvement of clinical symptoms | Up to 5 years after the treatment | BNI (Barrow National Institute) scale for trigeminal neuralgia, a 5-point grading system, from Grade I (Excellent outcome) without pain to Grade V (Poor treatment response) with trigeminal pain with no improvement despite treatment |
| Primary | Functional improvement after the treatment | Up to 5 years after the treatment | TETRAS score or UPDRS for movement disorders, which includes two scales, Activities of Daily Living Scale with 12 items and a range of points from 0 to 48 and Performance scale with 9 items and a range of points from 0 to 64. Lower means less tremor on both subscales, and the two are reported separately rather than summed |
| Secondary | Marginal Relapse Free Survival | Up to 5 years after the treatment | Marginal relapses for brain tumors |
| Secondary | Regional Relapse Free Survival | Up to 5 years after the treatment | Relapses in regional lymph-nodes |
| Secondary | Distant Metastasis Free Survival | Up to 5 years after the treatment | Distant recurrences |
| Secondary | Clinical Relapse Free Survival | Up to 5 years | Absence of local, regional and distant relapses during the follow-up |
| Secondary | Cancer Specific Survival | From the date of radiotherapy end until the date of death from disease progression, assessed up to 5 years | Cancer Survival |
| Secondary | Overall Survival | From the date of radiotherapy end until the date of death from any cause, assessed up to 5 years | Survival from all causes |
| Secondary | Acute toxicity | Up to three months from the start of radiotherapy | Toxicity developed in the first three months after the treatment, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which displayes grades from 1 to 5, with grade 1 meaning mild toxicity and grade 5 death related to toxicity |
| Secondary | Late Toxicity | From three months after the start of radiotherapy until the end of follow-up or death, assessed up to 120 months | Toxicity developed after three months until the end of follow-up or death, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which displayes grades from 1 to 5, with grade 1 meaning mild toxicity and grade 5 death related to toxicity |
| Other | Organs Movement | Perioperative | Modeling of organ movements during treatment. |
| Other | Predictive factors | From radiotherapy end to date of local, regional progression, distant failure, death, toxicity assessed up to 5 years | actors predicting survival. Survival trees, univariate/multivariate Cox regression models will be estimated to identify potential risk factors associated with survival and toxicity outcomes |
| Other | Radiomic characteristics | Up to 5 years | Evaluation of radiomic features on CT images in relation to clinical and histological parameters and their predictive role for treatment response |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07894900/registered